Clinical trials: Metabolic Dysfunction Associated Steatotic Liver Disease
Alcohol-related Liver Disease, Metabolic Dysfunction Associated Steatotic Liver Disease
Investigating Myosteatosis in Steatotic Liver Diseases
Steatotic liver diseases (SLD) are the most common chronic liver diseases worldwide. SLD are defined by an excessive liver lipid content (steatosis) of more than 5% of the total liver weight and includes 3 clinical entities …
- Conditions
- Alcohol-related Liver Disease, Metabolic Dysfunction Associated Steatotic Liver Disease, Steatotic Liver Disease of Mixed Origin (MetALD), Steatotic Liver Diseases
- Trial name
- MYO-SLD (NCT06514300)
- Where
- Belgium
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Type 2 Diabetes Mellitus, Metabolic Dysfunction-associated Steatotic Liver Disease
Liver Fat as a Dietary Target of the Chinese Medical Nutrition Therapy (CMNT) Diet for Treating Type 2 Diabetes With Nonalcoholic Fatty Liver Disease (Version 3.0)
This study aims to explore the efficacy of CMNT, an intermittent energy restriction (iER) intervention, in managing Chinese adults with type 2 diabetes and non-alcoholic fatty liver disease.
- Trial name
- NCT07083336
- Testing
- CMNT diet
- Where
- 3 sites in China
- Volunteers
- 120 people
- Sponsor
- State Key Laboratory of Subhealth Intervention Technology
Metabolic Dysfunction-Associated Steatotic Liver Disease, Diabetes Mellitus Type 2
Effects of iGlarLixi Versus iGlar on Liver Fat Content in Patients With Type 2 Diabetes Mellitus Combined With Metabolic Dysfunction-associated Steatotic Liver Disease
This is a single-center, randomized, open-label, controlled clinical trial to compare the effects of a fixed-ratio combination of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) versus insulin glargine 100 U/mL (iGlar) on…
- Trial name
- NCT07274644
- Testing
- iGlarLixi, IGlar U100
- Where
- China
- Volunteers
- 36 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
HIV Infections, Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) & Steatohepatitis (MASH)
Metabolic Liver Disease in Newly Diagnosed People Living With HIV (MASHIV-TR)
This study aims to identify the risk factors that lead to the development of metabolic liver disease in people who have been newly diagnosed with HIV.
- Conditions
- HIV Infections, Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) & Steatohepatitis (MASH), Fatty Liver
- Trial name
- MASHIV-TR (NCT07737340)
- Testing
- FibroScan (Transient Elastography), Hepatobiliary Ultrasonography (USG), Clinical and Laboratory Monitoring
- Where
- 11 sites in Turkey (Türkiye)
- Volunteers
- 411 people, healthy volunteers welcome
- Sponsor
- Yaşar Bayındır, MD
Metabolic Dysfunction-associated Steatotic Liver Disease
Guerbet Liver Fibrosis
The goal of this study is to assess the value of liver dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and texture analysis post gadopiclenol for liver fibrosis staging, in comparison with MR elastography, T1…
- Trial name
- NCT06703450
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Type 1 Diabetes
Butyrate or Intensive Lifestyle Modification in Type 1 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent in individuals with type 1 diabetes (T1D) and is associated with increased cardiovascular and metabolic risk.
- Trial name
- NCT07684248
- Testing
- Intensive lifestyle modification (hypocaloric Mediterranean diet and promotion of physical activity), Butyrate, Intensive lifestyle modification + butyrate
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Effects of Long-lasting Bicarbonate-Sulfate-Calcium-Magnesium Water Intake on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Related Outcome
Background: Fonte Essenziale®, a mineral water rich in bicarbonate, sulphate, calcium, and magnesium, has shown potential in modulating the gut-liver axis and microbiota in hepatic steatosis.
- Trial name
- FonteESSEMASLD (NCT07211113)
- Testing
- Fonte Essenziale® mineral water
- Where
- Italy
- Volunteers
- 87 people
- Sponsor
- University of Campania Luigi Vanvitelli
MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
Prevalence and Clinical Significance of Hematological Abnormalities in Patients With Clinically Diagnosed Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Case-Control Study
this study aims to investigate the prevalence of hematological abnormalities among patients with clinically diagnosed MASLD, evaluate their clinical correlates, and examine their association with non-invasive fibrosis scores.
- Trial name
- MASLD (NCT07872059)
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Assiut University
Fatty Liver Disease
A Clinical Study of Ultrasound-derived Fat Fraction to Assess Metabolic Dysfunction-Associated Steatotic Liver Disease
Aims: To evaluate the diagnostic performance of ultrasound-derived fat fraction (UDFF) in assessing the degree of hepatic steatosis in an obese population, with liver biopsy as reference standard.
- Trial name
- NCT06487325
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Ma Zhe
Metabolic-dysfunction Associated Steatotic Liver Disease
SMART Diets for MASLD
This phase 2 trial is a single-site sequential, multiple assignment, randomized trial (SMART) to test and construct a high-quality adaptive intervention of essential amino acids (EAA) and/or Low Sugar Diet for children with…
- Trial name
- NCT07459504
- Testing
- Essential Amino Acids Supplementation intervention, Low sugar diet
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Michigan State University
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Overweight
EVOO and Metabolic Liver Health in MASLD
MASLD is currently one of the most common chronic non-communicable diseases and the leading cause of liver-related mortality and morbidity, with a rising prevalence worldwide, especially in the presence of obesity, diabetes, and…
- Trial name
- EvoLiveR (NCT07412444)
- Testing
- Oil Supplementation - 3 tablespoons of oil, 9 Tablespoons of Oil
- Where
- Italy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Healthy, Fatty Liver
Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease
A generic screening study to establish structural and/or functional baselines of specific organs.
- Conditions
- Healthy, Fatty Liver, MASLD, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
- Trial name
- MASLD (NCT04873258)
- Testing
- Bioimpedence Vector Analysis
- Where
- United Kingdom
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Richmond Research Institute
Metabolic Dysfunction-Associated SteatoHepatitis (MASH)
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
This study is researching an investigational drug, ALN-HSD called "study drug". This study is focused on participants who are known to have Metabolic dysfunction-Associated SteatoHepatitis (MASH).
- Trial name
- NASHGEN-2 (NCT05519475)
- Testing
- ALN-HSD
- Where
- 71 sites in United States, Japan and 2 more
- Volunteers
- 120 people
- Sponsor
- Regeneron Pharmaceuticals
MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
GLUT-F Improves MASLD Liver Function
This randomized, double-blind, placebo-controlled, two-period crossover study evaluated the effects of GLUT-F, a nutraceutical formulation containing silibin-enriched silymarin, glutathione, and vitamin E delivered with…
- Trial name
- GLUT-F (NCT07724067)
- Testing
- GLUTatios FOrte
- Where
- Italy
- Volunteers
- 42 people
- Sponsor
- University of Bari
Metabolic Dysfunction-Associated Steatotic Liver Disease
Effect of Indianized Version of Mediterranean Diet vs. Low Fat Diet on Hepatic Steatosis in Overweight Children and Adolescent With MASLD
NAFLD encompasses the entire spectrum of Fatty liver disease in individuals without significant alcohol consumption, ranging from fatty liver to steatohepatitis to cirrhosis.
- Trial name
- NCT06768216
- Testing
- Indianized version of Mediterranean Diet, Low Fat Diet, Physical Activity
- Where
- India
- Volunteers
- 134 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Metabolic Dysfunction-Associated Steatotic Liver Disease, Non Celiac Wheat Sensitivity
Liver Steatosis and Fibrosis in Non-Celiac Wheat Sensitivity Patients: a Prospective Study
Hypothesizing an intestinal barrier impairment as a common pathophysiological substrate of both Non Celiac Wheat Sensitivity (NCWS) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MAFLD), in a retrospective cohort…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Non Celiac Wheat Sensitivity, Irritable Bowel Syndrome, Functional Dyspepsia
- Trial name
- NCT07750535
- Testing
- Prevalence and severity of liver steatosis and fibrosis,
- Where
- 2 sites in Italy
- Volunteers
- 250 people
- Sponsor
- University of Palermo
Metabolic Dysfunction-Associated Steatotic Liver Disease, Hepatocellular Carcinoma
Prognostic Factors for HCC and Liver Transplantation in Patients With MASLD/MASH
The BOMASH study is a single-center, prospective/retrospective observational study without pharmacological interventions. It will include all patients diagnosed with Metabolic-Associated Steatotic Liver Disease (MASLD/MASH)…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Hepatocellular Carcinoma, Metabolic Dysfunction-Associated Steatohepatitis, Liver Transplant
- Trial name
- BOMASH (NCT06813508)
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
Combination of CXD and Restrictive Ketogenic Diet Against MASLD
This study employed a single-center, randomized, investigator-blind, three-group parallel, stepwise controlled clinical trial. A total of 135 subjects were randomly assigned to receive either a low-carbohydrate diet intervention…
- Trial name
- NCT07639866
- Testing
- Low-carbon control group, KD group, CXD and KD group
- Volunteers
- 135 people
- Sponsor
- Shanghai Municipal Hospital of Traditional Chinese Medicine
Plaque Psoriasis, Metabolic Dysfunction-Associated Steatotic Liver Disease
A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD
This study aims to examine the retention rate of secukinumab in adult patients with plaque psoriasis (with or without psoriatic arthritis [PsA]) and metabolic dysfunction-associated steatotic liver disease (MASLD) in routine…
- Trial name
- SEC-HOPE (NCT07683065)
- Where
- 7 sites in Spain
- Volunteers
- 150 people
- Sponsor
- Novartis Pharmaceuticals
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, NAFLD - Non-Alcoholic Fatty Liver Disease
Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis
The research study is considering a non-invasive way to measure the percentage of fat in the liver using ultrasound. This could help detect early signs of a very common condition called metabolic dysfunction-associated steatotic…
- Trial name
- LYNX (NCT07270601)
- Testing
- Verasonics NXT Data Acquisition System, Philips EPIQ Elite, EchoSense FibroScan
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- ContextVision AB